Stringer M D, Steadman C A, Kakkar V V
Thrombosis Research Unit, King's College Hospital, London, England.
Curr Med Res Opin. 1990;12(4):207-14. doi: 10.1185/03007999009111649.
The effects of gemfibrozil were assessed in 27 hyperlipidaemic patients with stable peripheral arterial occlusive disease. Gemfibrozil (600 mg twice daily) was administered for 12 weeks after 2 weeks of placebo medication, thus enabling patients to act as their own controls. Serum cholesterol levels were reduced by a mean of 11.3%, triglycerides by 42.3% and low density lipoprotein cholesterol by 19.9%. Small but significant increases in HDL3 and apolipoprotein A-II also occurred. New findings included significant reductions in plasma lipid peroxides and Factor VIIc levels and a mean increase of 19% in antithrombin III concentrations. Furthermore, plasma fibrinogen levels increased by a mean of 17.6%, a potentially adverse effect of gemfibrozil that has not been previously reported.
在27名患有稳定型外周动脉闭塞性疾病的高脂血症患者中评估了吉非贝齐的效果。在服用2周安慰剂后，给予吉非贝齐（每日两次，每次600毫克），持续12周，这样患者就可以作为自身对照。血清胆固醇水平平均降低了11.3%，甘油三酯降低了42.3%，低密度脂蛋白胆固醇降低了19.9%。高密度脂蛋白3和载脂蛋白A-II也有小幅但显著的升高。新发现包括血浆脂质过氧化物和因子VIIc水平显著降低，抗凝血酶III浓度平均升高19%。此外，血浆纤维蛋白原水平平均升高了17.6%，这是吉非贝齐一个此前未被报道过的潜在不良反应。
